Slower decline of renal function after initiation of rosiglitazone in diabetics - A pilot study

Clinical Nephrology

Volumn 72, Issue 3, 2009, Pages 181-185

  Trivedi, H ^a,d   Lu, N ^b   Andresen, B T ^c   Whaley Connell, A ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d NONE   (United States)

Author keywords

Chronic kidney disease; Pogression; Rosiglitazone; Thiazolidinediones

Indexed keywords

CREATININE; HEMOGLOBIN A1C; ROSIGLITAZONE;

AGED; ARTICLE; BLOOD PRESSURE; CREATININE BLOOD LEVEL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; REACTION TIME; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PILOT PROJECTS; RENAL INSUFFICIENCY; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 70350142342     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.2379/CN106150     Document Type: Article

References (24)

1. Agarwal R, Saha C, Battiwala M, Vasavada N, Curley T, Chase SD, Sachs N, Semret MH. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int. 2005; 68: 285-292.
2. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med. 2004; 116: 230-235.
3. Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, Porter LE. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006; 24: 2047-2055.
4. Bao Y, Jia RH, Yuan J, Li J. Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacology. 2007; 80: 57-64.
5. Baylis C, Atzpodien EA, Freshour G, Engels K. Peroxisome proliferator-activated receptor gamma agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther. 2003; 307: 854-860.
6. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-869.
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003; 289: 2560-2571.
8. Fujiwara K, Hayashi K, Ozawa Y, Tokuyama H, Nakamura A, Saruta T. Renal protective effect of troglitazone in Wistar fatty rats. Metabolism. 2000; 49: 1361-1364.
9. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004; 27: 141-147.
10. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV, for the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med. 2007; 357: 28-38.
11. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. 2001; 59: 1899-1910.
12. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005; 21: 167-174.
13. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2006; 356: 2457-2471.
14. Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, Wada J, Shikata Y, Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol. 2007; 292: 1141-1150.
15. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes. 2005; 54: 2206-2211.
16. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993; 118: 577-581.
17. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006; 70: 1223-1233.
18. The DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: Results of the Diabetes Reduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008; 31: 1007-1014.
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
20. United States Renal Data System. 2006 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006. http://www.usrds.org.
21. United States Renal Data System. 2000 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2000. http://www.usrds.org.
22. Yanagawa T, Araki A, Sasamoto K, Shirabe S, Yamanouchi T. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism. 2004; 53: 353-357.
23. Yoshida K, Kohzuki M, Xu HL, Wu X, Kamimoto M, Sato T. Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure. J Hyperten. 2001; 19: 503-510.
24. Yu X, Li C, Li X, Cai L. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1. Toxicol Sci. 2007; 96: 346-356.